Funding for this research was provided by:
Eli Lilly and Company (Not appplicable)
Received: 19 January 2021
Accepted: 19 May 2021
First Online: 25 June 2021
: This study was conducted in compliance with Good Clinical Practice guidelines, including International Conference on Harmonization Guidelines. In addition, all applicable local laws and regulatory requirements were adhered to throughout the study. Before recruiting participants, all study documents were submitted and approved by the Copernicus Group Independent Review Board; approval number is 20182658.
: Not applicable.
: LD and TH are employees and shareholders of Eli Lilly and Company which provided financial support for this study. LN, UC, JC, and TS are employees of Clinical Outcomes Solutions, who designed and undertook this research.